Merck Diabetes Drug Trial Meets Primary Endpoint
Treatment with Sitagliptin did not increase risk of cardiovascular events in primary composite endpoint, or hospitalization for heart failure, compared with placebo
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Endocrinology | Heart | Heart Failure | Januvia | Merck | Pharmaceuticals